ASCO® 2024 Highlights: Presenter Vignette – Brian Rini

Dr. Brian Rini

Brian Rini

MD, FASCO

Vanderbilt-Ingram Cancer Center

Abstract# 4505

Biomarker analysis of the phase 3 KEYNOTE-426 study of pembrolizumab (P) plus axitinib (A) versus sunitinib (S) for advanced renal cell carcinoma (RCC).